Market revenue in 2023 | USD 108.1 million |
Market revenue in 2030 | USD 152.0 million |
Growth rate | 5% (CAGR from 2023 to 2030) |
Largest segment | Infectious diseases |
Fastest growing segment | Oncology |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Oncology, Prenatal Testing, Endocrinology, Other Applications, Hematology, Infectious Diseases |
Key market players worldwide | Roche, Abbott Laboratories, Qiagen NV, Bayer AG, Nova Biomedical, Danaher Corp, Nipro Corp, Bio-Rad Laboratories Inc, Agilent Technologies Inc, BioMerieux SA, OraSure Technologies Inc, Abaxis |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to point-of-care molecular diagnostics market will help companies and investors design strategic landscapes.
Infectious diseases was the largest segment with a revenue share of 93.62% in 2023. Horizon Databook has segmented the Spain point-of-care molecular diagnostics market based on oncology, prenatal testing, endocrinology, other applications, hematology, infectious diseases covering the revenue growth of each sub-segment from 2018 to 2030.
Spain’s POC molecular diagnostics market is expected to register significant growth over the forecast period owing to strategies being implemented along with funding initiatives undertaken by key companies & several associations to promote POCT in the country. For instance, in July 2019, EIT Health Spain stated that 15 startup companies were selected for 2019 Head start support, which involves mentoring, funding, and networking opportunities for them.
Among these 15 startup firms, Moirai Biodesign is a biotechnology company focused on developing an end-to-end, near-patient, affordable, and fast molecular diagnostics platform, Kloto-DX, used for the determination of the etiology of sepsis. This initiative supported the development of the Kloto-DX kit in POC settings, thereby boosting the company’s growth in Spain.
As per WHO, the country witnessed more than 11 million COVID-19 cases between January 2020 and May 2022, leading to around 104,000 deaths. This is anticipated to offer lucrative opportunities for testing kit manufacturers in Spain.
Horizon Databook provides a detailed overview of country-level data and insights on the Spain point-of-care molecular diagnostics market , including forecasts for subscribers. This country databook contains high-level insights into Spain point-of-care molecular diagnostics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account